Dihydrotestosterone and testosterone levels in men screened for prostate cancer: A study of a randomized population

被引:28
|
作者
Gustafsson, O
Norming, U
Gustafsson, S
Eneroth, P
Astrom, G
Nyman, CR
机构
[1] STOCKHOLM SODER HOSP,DEPT CLIN CHEM,S-11883 STOCKHOLM,SWEDEN
[2] NOVUM HUDDINGE HOSP,KAROLINSKA INST,CLIN RES CTR,UNIT APPL BIOCHEM,HUDDINGE,SWEDEN
来源
BRITISH JOURNAL OF UROLOGY | 1996年 / 77卷 / 03期
关键词
dihydrotestosterone; testosterone; sexual-hormones; prostate cancer; screening;
D O I
10.1046/j.1464-410X.1996.89120.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the possible relationship between serum levels of prostate specific antigen (PSA), dihydrotestosterone (DHT), testosterone, sexual-hormone binding globulin (SHBG) and tumour stage, grade and ploidy in 65 cases of prostate cancer diagnosed in a screening study compared to 130 controls from the same population. Patients, subjects and methods From a population of 26 602 men between the ages of 55 and 70 years, 2400 were selected randomly and invited to undergo screening for prostate cancer using a digital rectal examination, transrectal ultrasonography and PSA analysis. Among the 1782 attendees, 65 cases of prostate cancer were diagnosed. Each case was matched with two control subjects of similar age and prostate volume from the screening population. Frozen serum samples were analysed for PSA, DHT, testosterone and SHBG, and compared to the diagnosis and tumour stage, grade and ploidy. Comparisons between these variables, and multivariate and regression analyses were performed. Results There were significant differences in PSA level with all variables except tumour ploidy, DHT levels were slightly lower in patients with prostate cancer but the difference was not statistically significant. There was a trend towards lower DHT values in more advanced tumours and the difference for T-stages was close to statistical significance (P=0.059). Testosterone levels were lower in patients with cancer than in the control group, but the differences were not significant. There was no correlation between testosterone levels, tumour stage and ploidy, but the differences in testosterone level in tumours of a low grade of differentiation compared to those with intermediate and high grade was nearly significant (P=0.058). The testosterone/DHT ratio tended to be higher in patients with more advanced tumours, SHBG levels were lower in patients with cancer than in controls but the differences were not statistically significant. There were no systematic variations of tumour stage, grade and ploidy, Multivariate analysis showed that if the PSA level was known, then DHT, testosterone or SHBG added no further information concerning diagnosis, stage, grade or ploidy, Regression analysis on T-stage, PSA level and DHT showed an inverse linear relationship between PSA and DHT for stage T-3 (P=0.035), but there was no relationship between PSA and testosterone. Conclusion PSA was of value in discriminating between cases and controls and between various tumour stages and grades, but no statistically significant correlation was found for ploidy. If PSA level was known, no other variable added information in individual cases, Within a group, DHT levels tended to be lower among cases and in those with more advanced tumours, There was an inverse relationship between tumour volume, as defined by PSA level, and 5 alpha-reductase activity, as defined by DHT level, and the testosterone/DHT ratio. This trend was most obvious with T-stage, No systematic variation were found in the levels of testosterone or SHBG.
引用
收藏
页码:433 / 440
页数:8
相关论文
共 50 条
  • [21] Prostate cancer in men using testosterone supplementation
    Gaylis, FD
    Lin, DW
    Ignatoff, JM
    Amling, CL
    Tutrone, RF
    Cosgrove, DJ
    JOURNAL OF UROLOGY, 2005, 174 (02) : 534 - 538
  • [22] Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors
    Wu, Yue
    Godoy, Alejandro
    Azzouni, Faris
    Wilton, John H.
    Ip, Clement
    Mohler, James L.
    PROSTATE, 2013, 73 (13) : 1470 - 1482
  • [23] RE: Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer
    Traish, Abdulmaged M.
    Morgentaler, Abraham
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2013, 138 : 462 - 462
  • [24] Significance of Pretreatment Testosterone Levels in Prostate Cancer Risk Groups
    Celik, Serdar
    Bozkurt, Ozan
    Yildiz, Hueyin Alperen
    Demir, Omer
    Tuna, Burcin
    Yorukoglu, Kutsal
    Aslan, Guven
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2016, 15 (03): : 98 - 102
  • [25] Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer
    Campbell, Tessa J.
    Tindall, Donald J.
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2012, 13 (05) : 237 - 238
  • [26] Testosterone replacement in prostate cancer survivors with testosterone deficiency: Study protocol of a randomized controlled trial
    Valderrabano, Rodrigo J.
    Pencina, Karol
    Storer, Thomas W.
    Reid, Kieran F.
    Kibel, Adam S.
    Burnett, Arthur L.
    Huang, Grace
    Dorff, Tanya
    Privat, Fabiola
    Ghattas-Puylara, Catherine
    Wilson, Lauren
    Latham, Nancy K.
    Holmberg, Mats
    Bhasin, Shalender
    ANDROLOGY, 2023, 11 (01) : 93 - 102
  • [27] Testosterone and Prostate Cancer: What are the Risks for Middle-Aged Men?
    Morgentaler, Abraham
    UROLOGIC CLINICS OF NORTH AMERICA, 2011, 38 (02) : 119 - +
  • [28] Testosterone, dihydrotestosterone, bone density, and hip fracture risk among older men: The Cardiovascular Health Study
    Rosenberg, Emily A.
    Buzkova, Petra
    Fink, Howard A.
    Robbins, John A.
    Shores, Molly M.
    Matsumoto, Alvin M.
    Mukamal, Kenneth J.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 114
  • [29] Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants
    Dias, Alexander
    Brook, Mark N.
    Bancroft, Elizabeth K.
    Page, Elizabeth C.
    Chamberlain, Anthony
    Saya, Sibel
    Amin, Jan
    Mikropoulos, Christos
    Taylor, Natalie
    Myhill, Kathryn
    Thomas, Sarah
    Saunders, Edward
    Dadaev, Tokhir
    Leongamornlert, Daniel
    Jensen, Thomas Dyrso
    Evans, D. Gareth
    Cybulski, Cezary
    Liljegren, Annelie
    Teo, Soo H.
    Side, Lucy
    Kote-Jarai, Zsofia
    Eeles, Rosalind A.
    BJUI COMPASS, 2023, 4 (03): : 361 - 373
  • [30] Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment
    Garcia-Cruz, Eduardo
    Piqueras, Marta
    Huguet, Jorge
    Peri, Lluis
    Izquierdo, Laura
    Musquera, Mireia
    Franco, Agustin
    Alvarez-Vijande, Ricardo
    Jose Ribal, Maria
    Alcaraz, Antonio
    BJU INTERNATIONAL, 2012, 110 (11B) : E541 - E546